Found: 187
Select item for more details and to access through your institution.
Transposon DNA sequences facilitate the tissue-specific gene transfer of circulating tumor DNA between human cells.
- Published in:
- Nucleic Acids Research, 2024, v. 52, n. 13, p. 7539, doi. 10.1093/nar/gkae427
- By:
- Publication type:
- Article
Prophylactic tocilizumab to prevent cytokine release syndrome (CRS) with teclistamab: A single-center experience.
- Published in:
- Blood Cancer Journal, 2023, v. 13, n. 1, p. 1, doi. 10.1038/s41408-023-00963-y
- By:
- Publication type:
- Article
Expert Consensus on the Incorporation of Anti-CD38 Monoclonal Antibody Therapy Into the Management of Newly Diagnosed Multiple Myeloma.
- Published in:
- Clinical Lymphoma, Myeloma & Leukemia, 2023, v. 23, n. 11, p. 815, doi. 10.1016/j.clml.2023.07.001
- By:
- Publication type:
- Article
Late versus early response and depth of response are associated with improved outcomes in patients with newly diagnosed multiple myeloma enrolled in the TOURMALINE‐MM2 trial.
- Published in:
- EJHaem, 2023, v. 4, n. 4, p. 995, doi. 10.1002/jha2.759
- By:
- Publication type:
- Article
Monitoring, prophylaxis, and treatment of infections in patients with MM receiving bispecific antibody therapy: consensus recommendations from an expert panel.
- Published in:
- Blood Cancer Journal, 2023, v. 13, n. 1, p. 1, doi. 10.1038/s41408-023-00879-7
- By:
- Publication type:
- Article
Chimeric antigen receptor T‐cell therapy in multiple myeloma: A comprehensive review of current data and implications for clinical practice.
- Published in:
- CA: A Cancer Journal for Clinicians, 2023, v. 73, n. 3, p. 275, doi. 10.3322/caac.21771
- By:
- Publication type:
- Article
Novel Approaches to the Treatment of Multiple Myeloma.
- Published in:
- Clinical Advances in Hematology & Oncology, 2023, v. 21, n. 5, p. 247
- By:
- Publication type:
- Article
Eliminating the monitoring period with subcutaneous daratumumab: a single-center experience.
- Published in:
- Blood Cancer Journal, 2023, v. 13, n. 1, p. 1, doi. 10.1038/s41408-023-00801-1
- By:
- Publication type:
- Article
A pooled analysis of outcomes according to cytogenetic abnormalities in patients receiving ixazomib- vs placebo-based therapy for multiple myeloma.
- Published in:
- Blood Cancer Journal, 2023, v. 13, n. 1, p. 1, doi. 10.1038/s41408-022-00768-5
- By:
- Publication type:
- Article
Eliminating the monitoring period with subcutaneous daratumumab: a single-center experience.
- Published in:
- 2023
- By:
- Publication type:
- Letter
Optimizing the Benefits of BCMA-Targeted CAR T-Cell Therapy in Multiple Myeloma.
- Published in:
- Clinical Advances in Hematology & Oncology, 2023, v. 21, n. 1, p. 43
- By:
- Publication type:
- Article
Smoldering multiple myeloma current treatment algorithms.
- Published in:
- Blood Cancer Journal, 2022, v. 12, n. 9, p. 1, doi. 10.1038/s41408-022-00719-0
- By:
- Publication type:
- Article
Venetoclax ex vivo functional profiling predicts improved progression-free survival.
- Published in:
- Blood Cancer Journal, 2022, v. 12, n. 8, p. 1, doi. 10.1038/s41408-022-00710-9
- By:
- Publication type:
- Article
Treatment Options for Patients With Heavily Pretreated Relapsed and Refractory Multiple Myeloma.
- Published in:
- Clinical Lymphoma, Myeloma & Leukemia, 2022, v. 22, n. 7, p. 460, doi. 10.1016/j.clml.2022.01.011
- By:
- Publication type:
- Article
ATLAS: Risk-adapted Triplet Maintenance with Carfilzomib, Lenalidomide and Dexamethasone - Still Shrugging?
- Published in:
- touchREVIEWS in Oncology & Haematology, 2022, v. 18, n. 2, p. 96, doi. 10.17925/OHR.2022.18.2.96
- By:
- Publication type:
- Article
Emerging Therapies for Relapsed/ Refractory Multiple Myeloma.
- Published in:
- Oncology (08909091), 2022, v. 36, n. 5, p. 330
- By:
- Publication type:
- Article
Generation of human long-lived plasma cells by developmentally regulated epigenetic imprinting.
- Published in:
- Life Science Alliance, 2022, v. 5, n. 3, p. 1, doi. 10.26508/lsa.202101285
- By:
- Publication type:
- Article
Impact of concurrent gabapentin or pregabalin with high‐dose melphalan in patients with multiple myeloma undergoing autologous hematopoietic stem cell transplant.
- Published in:
- Pharmacotherapy, 2022, v. 42, n. 3, p. 233, doi. 10.1002/phar.2667
- By:
- Publication type:
- Article
"I took the road less traveled, and that has made all the difference": Making a case for high-dose therapy and autologous stem cell transplantation in elderly patients with newly diagnosed multiple myeloma.
- Published in:
- 2021
- By:
- Publication type:
- editorial
Longer term outcomes with single‐agent belantamab mafodotin in patients with relapsed or refractory multiple myeloma: 13‐month follow‐up from the pivotal DREAMM‐2 study.
- Published in:
- Cancer (0008543X), 2021, v. 127, n. 22, p. 4198, doi. 10.1002/cncr.33809
- By:
- Publication type:
- Article
OAB-013: Iberdomide (IBER) in combination with dexamethasone (DEX) and daratumumab (DARA), bortezomib (BORT), or carfilzomib (CFZ) in patients (pts) with relapsed/refractory multiple myeloma (RRMM).
- Published in:
- Clinical Lymphoma, Myeloma & Leukemia, 2021, v. 21, p. S9, doi. 10.1016/S2152-2650(21)02087-5
- By:
- Publication type:
- Article
OAB-027: Idecabtagene vicleucel (ide-cel, bb2121), a BCMA-directed CAR T-cell therapy, for the treatment of patients with relapsed and refractory multiple myeloma (RRMM): updated results from KarMMa.
- Published in:
- Clinical Lymphoma, Myeloma & Leukemia, 2021, v. 21, p. S17, doi. 10.1016/S2152-2650(21)02101-7
- By:
- Publication type:
- Article
OAB-052: Impact of chromosome 1 abnormalities on newly diagnosed multiple myeloma treated with proteasome inhibitor, immunomodulatory drug, and dexamethasone: analysis from the ENDURANCE ECOG-ACRIN E1A11 trial.
- Published in:
- Clinical Lymphoma, Myeloma & Leukemia, 2021, v. 21, p. S33, doi. 10.1016/S2152-2650(21)02126-1
- By:
- Publication type:
- Article
P-170: Transplant related morbidities with Melphalan as conditioning regimen for myeloma autotransplants.
- Published in:
- Clinical Lymphoma, Myeloma & Leukemia, 2021, v. 21, p. S129, doi. 10.1016/S2152-2650(21)02297-7
- By:
- Publication type:
- Article
P-202: Characterization of ocular adverse events in patients receiving Belantamab Mafadotin for ≥12 months: post-hoc analysis of DREAMM-2 study in relapsed/refractory Multiple Myeloma.
- Published in:
- Clinical Lymphoma, Myeloma & Leukemia, 2021, v. 21, p. S149, doi. 10.1016/S2152-2650(21)02329-6
- By:
- Publication type:
- Article
P-203: EXCALIBER: a phase 3 study comparing iberdomide, daratumumab, and dexamethasone (IberDd) with daratumumab, bortezomib, and dexamethasone (DVd) in patients with relapsed or refractory multiple myeloma.
- Published in:
- Clinical Lymphoma, Myeloma & Leukemia, 2021, v. 21, p. S150, doi. 10.1016/S2152-2650(21)02330-2
- By:
- Publication type:
- Article
Keeping Myeloma in Check: The Past, Present and Future of Immunotherapy in Multiple Myeloma.
- Published in:
- Cancers, 2021, v. 13, n. 19, p. 4787, doi. 10.3390/cancers13194787
- By:
- Publication type:
- Article
Daratumumab Plus Carfilzomib, Lenalidomide, and Dexamethasone in Patients With Newly Diagnosed Multiple Myeloma.
- Published in:
- Clinical Lymphoma, Myeloma & Leukemia, 2021, v. 21, n. 10, p. 701, doi. 10.1016/j.clml.2021.05.017
- By:
- Publication type:
- Article
Poster: ABCL-378: Prolonged Cytopenias in Autologous Stem Cell Transplantation in Relapsed/Refractory Diffuse Large B-Cell Lymphoma.
- Published in:
- Clinical Lymphoma, Myeloma & Leukemia, 2021, v. 21, p. S240, doi. 10.1016/S2152-2650(21)01509-3
- By:
- Publication type:
- Article
Poster: MM-078: Characterization of Ocular Adverse Events in Patients Receiving Belantamab Mafodotin (Belamaf) for ≥ 12 Months: Post Hoc Analysis of DREAMM-2 Study in Relapsed/Refractory Multiple Myeloma (RRMM).
- Published in:
- Clinical Lymphoma, Myeloma & Leukemia, 2021, v. 21, p. S251, doi. 10.1016/S2152-2650(21)01576-7
- By:
- Publication type:
- Article
ABCL-378: Prolonged Cytopenias in Autologous Stem Cell Transplantation in Relapsed/Refractory Diffuse Large B-Cell Lymphoma.
- Published in:
- Clinical Lymphoma, Myeloma & Leukemia, 2021, v. 21, p. S396, doi. 10.1016/S2152-2650(21)01898-X
- By:
- Publication type:
- Article
MM-078: Characterization of Ocular Adverse Events in Patients Receiving Belantamab Mafodotin (Belamaf) for ≥12 Months: Post Hoc Analysis of DREAMM-2 Study in Relapsed/Refractory Multiple Myeloma (RRMM).
- Published in:
- Clinical Lymphoma, Myeloma & Leukemia, 2021, v. 21, p. S419, doi. 10.1016/S2152-2650(21)01940-6
- By:
- Publication type:
- Article
Novel Approaches to Treating Relapsed and Refractory Multiple Myeloma with a Focus on Recent Approvals of Belantamab Mafodotin and Selinexor.
- Published in:
- Clinical Pharmacology, 2021, v. 13, p. 169, doi. 10.2147/CPAA.S288840
- By:
- Publication type:
- Article
Management of belantamab mafodotin-associated corneal events in patients with relapsed or refractory multiple myeloma (RRMM).
- Published in:
- Blood Cancer Journal, 2021, v. 11, n. 5, p. 1, doi. 10.1038/s41408-021-00494-4
- By:
- Publication type:
- Article
Targeted Therapy Treatment Options for Patients With Relapsed/Refractory Multiple Myeloma.
- Published in:
- Oncology (08909091), 2021, v. 35, n. 5, p. 284
- By:
- Publication type:
- Article
Novel Treatment Advances and Approaches in the Management of Relapsed/Refractory Multiple Myeloma: Expert Strategies on the Role of Emerging Therapies.
- Published in:
- Journal of Managed Care Medicine, 2021, v. 24, n. 2, p. 33
- By:
- Publication type:
- Article
Natural history of multiple myeloma patients refractory to venetoclax: A single center experience.
- Published in:
- American Journal of Hematology, 2021, v. 96, n. 3, p. E68, doi. 10.1002/ajh.26064
- By:
- Publication type:
- Article
Antibody Treatment in Multiple Myeloma.
- Published in:
- Clinical Advances in Hematology & Oncology, 2021, v. 19, n. 3, p. 166
- By:
- Publication type:
- Article
Overall survival with oral selinexor plus low‐dose dexamethasone versus real‐world therapy in triple‐class‐refractory multiple myeloma.
- Published in:
- EJHaem, 2021, v. 2, n. 1, p. 48, doi. 10.1002/jha2.120
- By:
- Publication type:
- Article
Daratumumab With Cetrelimab, an Anti-PD-1 Monoclonal Antibody, in Relapsed/Refractory Multiple Myeloma.
- Published in:
- 2021
- By:
- Publication type:
- journal article
Downregulation of PA28α induces proteasome remodeling and results in resistance to proteasome inhibitors in multiple myeloma.
- Published in:
- Blood Cancer Journal, 2020, v. 10, n. 12, p. 1, doi. 10.1038/s41408-020-00393-0
- By:
- Publication type:
- Article
Phase 1 Trial Evaluating Vorinostat Plus Bortezomib, Lenalidomide, and Dexamethasone in Patients With Newly Diagnosed Multiple Myeloma.
- Published in:
- 2020
- By:
- Publication type:
- journal article
Corneal Epithelial Findings in Patients with Multiple Myeloma Treated with Antibody–Drug Conjugate Belantamab Mafodotin in the Pivotal, Randomized, DREAMM-2 Study.
- Published in:
- Ophthalmology & Therapy, 2020, v. 9, n. 4, p. 889, doi. 10.1007/s40123-020-00280-8
- By:
- Publication type:
- Article
Correction to: Corneal Epithelial Findings in Patients with Multiple Myeloma Treated with Antibody–Drug Conjugate Belantamab Mafodotin in the Pivotal, Randomized, DREAMM-2 Study.
- Published in:
- 2020
- By:
- Publication type:
- Correction Notice
Hitting a New Target in Multiple Myeloma: 'The future, to me, is really exciting.'.
- Published in:
- Oncology (08909091), 2020, v. 34, n. 11, p. 488, doi. 10.46883/onc.2020.3411.0488
- By:
- Publication type:
- Article
Single-agent belantamab mafodotin for relapsed/refractory multiple myeloma: analysis of the lyophilised presentation cohort from the pivotal DREAMM-2 study.
- Published in:
- Blood Cancer Journal, 2020, v. 10, n. 10, p. 1, doi. 10.1038/s41408-020-00369-0
- By:
- Publication type:
- Article
Phase 1 safety and pharmacodynamic study of lenalidomide combined with everolimus in patients with advanced solid malignancies with efficacy signal in adenoid cystic carcinoma.
- Published in:
- 2020
- By:
- Publication type:
- journal article
Elotuzumab, lenalidomide, and dexamethasone in RRMM: final overall survival results from the phase 3 randomized ELOQUENT-2 study.
- Published in:
- Blood Cancer Journal, 2020, v. 10, n. 1, p. N.PAG, doi. 10.1038/s41408-020-00357-4
- By:
- Publication type:
- Article
Message from the Chairmen.
- Published in:
- 2020
- By:
- Publication type:
- editorial
Updates in CAR T Therapy for Multiple Myeloma.
- Published in:
- Oncology (08909091), 2020, v. 34, n. 7, p. 283
- By:
- Publication type:
- Article